SEOM clinical guidelines for the treatment of renal cell carcinoma. - Wikidata - awgldk - TriplyDB

SEOM clinical guidelines for the treatment of renal cell carcinoma.

SEOM clinical guidelines for the treatment of renal cell carcinoma.

http://www.wikidata.org/entity/Q34553411

about

Review of renal cell carcinoma and its common subtypes in radiology Sequence of treatment in locally advanced and metastatic renal cell carcinoma Familial syndromes associated with neuroendocrine tumours TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition.Two cases of gallbladder metastasis from renal cell carcinoma and review of literature.Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.Renal Cancer in the Elderly.Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma.The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient.SEOM guidelines 2014: improving quality to increase its usefulness.Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.

P2860

Q26744297-12AB52B6-40AD-4518-A55B-7DDC40599389 Q26773653-5A6DFBC6-5783-4814-AD10-4D2799B7408E Q26777791-5A001368-31CC-414F-8461-B8DB7079E637 Q33429430-55D834C9-87CE-4F0B-8086-A406365D826B Q33442621-BD728694-CBBD-4EC1-BF96-7742BC32D348 Q33686273-A1064BA8-D5AE-4CF2-B722-98501C1E016C Q35828447-49B68C7A-1C93-4457-BB74-B2F37B9D68F0 Q36714797-0B7945AB-2D47-41D1-9F04-1A783985E481 Q38673512-9E4B1C89-8932-4728-80A0-0546893B8724 Q38682520-0EB0676F-530D-4214-AA66-396F8E309A6F Q38901871-6BCFFE7B-F7B9-409E-984B-792E51EDD169 Q39096266-148E261C-FF8B-456F-A075-D06C354F0499 Q39287099-1362CF64-E786-469D-9E39-F8E84B1F456D Q41080906-3918326B-6705-4817-B3B6-2B1BFF9D1B60 Q43019918-C6927461-656F-4B4C-8B42-E727F7791678 Q47101376-7A442ADA-8C00-44D8-99F0-0EE4CC6E616A

P2860

SEOM clinical guidelines for the treatment of renal cell carcinoma.

http://www.wikidata.org/entity/Q34553411

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

SEOM clinical guidelines for the treatment of renal cell carcinoma.

@ast

SEOM clinical guidelines for the treatment of renal cell carcinoma.

@en

SEOM clinical guidelines for the treatment of renal cell carcinoma.

@nl

type

label

SEOM clinical guidelines for the treatment of renal cell carcinoma.

@ast

SEOM clinical guidelines for the treatment of renal cell carcinoma.

@en

SEOM clinical guidelines for the treatment of renal cell carcinoma.

@nl

prefLabel

SEOM clinical guidelines for the treatment of renal cell carcinoma.

@ast

SEOM clinical guidelines for the treatment of renal cell carcinoma.

@en

SEOM clinical guidelines for the treatment of renal cell carcinoma.

@nl

P1433

Q34553411-013C35BC-90B8-456E-A313-FF4158A3FE55

P1476

Q34553411-37713F48-C2E1-4937-9E30-EA1E078A2251

P2093

Q34553411-80494FC9-E478-4E4D-90FA-A5F80AE8E9B5

Q34553411-91C3C3A0-EA6A-4B75-8DB4-FCAAD39C7B56

Q34553411-9BC79A52-A283-4348-970B-21852F3A2DBE

Q34553411-B5AC2DE2-9311-42CE-9995-16C2317C417E

Q34553411-C6A124F4-1443-48DE-84E1-E662B59463DF

Q34553411-C820F969-84C0-449F-AE40-7ADF5E245A69

Q34553411-EB1B7876-FE09-463C-B8AD-70CC5B6BD31B

P2860

Q34553411-0034C7CF-598D-40FC-B8B2-F0E87486D11C

Q34553411-00E6FBEB-9226-4075-AFD5-62FAD62CD58D

Q34553411-0228DC23-F4FF-4DCF-B68F-F1094DD4F82A

Q34553411-080FDBEE-3D06-40DF-B90B-22BE7333B4A8

Q34553411-089B2197-60C9-49E2-AEEF-470C14197924

Q34553411-0E8D7E8B-DDAC-4FB1-B5B2-E25932536B5D

Q34553411-0EFD5EAD-635F-43D0-9D5B-73C32D193184

Q34553411-1CEA1413-B437-43B4-83B6-FD27F5231CE6

Q34553411-2043BF26-C728-4A7E-B115-C83C8B8DF6D8

Q34553411-20F52950-5730-4C7C-A977-CFF893349965

P2888

Q34553411-5A483FE6-F0E5-4FEF-B9C5-970F0CBFAAD4

P304

Q34553411-BDC99B5E-0A54-4936-962E-CEA16AB7D7C8

P31

Q34553411-B5E0F8BE-6CCB-4443-9355-0D524CDAD4DB

P356

Q34553411-D964FD09-46DA-402D-9A33-7B0A441CEFC3

P433

Q34553411-2999B20E-DD5C-4D77-9667-736324BF4099

P478

Q34553411-11458A43-4C9B-4F37-B695-C9FE00EEC20D

P577

Q34553411-9769FB4D-DDFD-4EB6-BCAD-16559CC1CD01

P5875

Q34553411-E11612DB-ED4B-4632-B4E8-3A9CD8DFCA23

P698

Q34553411-057A3E1C-32F2-4C3E-983B-514E07541036

P932

Q34553411-FF763CAF-FEDE-4D7E-9010-22E235AA9B73

P356

S12094-014-1219-1

P1433

Clinical and Translational Oncology

P1476

SEOM clinical guidelines for the treatment of renal cell carcinoma.

@en

P2093

C Rodríguez

http://www.w3.org/2001/XMLSchema#string

I Duran

http://www.w3.org/2001/XMLSchema#string

J Bellmunt

http://www.w3.org/2001/XMLSchema#string

J Garcia de Muro

http://www.w3.org/2001/XMLSchema#string

J Puente

http://www.w3.org/2001/XMLSchema#string

N Lainez

http://www.w3.org/2001/XMLSchema#string

Spanish Society for Medical Oncology

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted therapies and the treatment of non-clear cell renal cell carcinoma

Comprehensive molecular characterization of clear cell renal cell carcinoma.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

P2888

s12094-014-1219-1

P304

1043-1050

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-014-1219-1

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266570677

http://www.w3.org/2001/XMLSchema#string

P698

25274276

http://www.w3.org/2001/XMLSchema#string

P932

4239764

http://www.w3.org/2001/XMLSchema#string